Abstract
Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFRmutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with afocus on ramucirumab+erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival, ramucirumab+erlotinib was comparable to osimertinib and dacomitinibin the primary analysis. Conclusion: The analysis showed ramucirumab+erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients withEGFRm+ advanced NSCLC. Registration information: PROSPERO ID: CRD42020136247.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
